Heart Failure and Kidney Disease

Grande, Dario; Gioia, Michele De; Terlizzese, Paola; Iacoviello, Massimo

doi:10.1007/5584_2017_126

Cited by 25 publications

(29 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Renal dysfunction is becoming a common abnormality in cardiovascular diseases and its burden may be often seen in HFrEF patients [8][9]. In our study, patients with chronic kidney disease with eGFR <60ml/min/1.73 m2 had more advanced age in comparison to other 2 groups.…”

Section: Discussionmentioning

confidence: 51%

The impact of renal function on clinical and biochemical characteristics in advanced heart failure patients

Bohdan¹,

Frankiewicz²,

Gruchała³

2019

Eur J Trans Clin Med

View full text Add to dashboard Cite

Background: Coexistence of heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease is associated with poor prognosis. We assessed the effect of renal function on exercise capacity and clinical parameters of patients with HF. Materials and methods: Forty five patients aged 58.2 ± 10.6 years with stable severe HFrEF were recruited. Patients were divided into 3 groups: group 1-eGFR: 30-59 ml/min/1.73 m2; group 2-eGFR: 60-89 ml/min/1.73 m2 and group 3-eGFR: ≥90 ml/min/1.73 m2. Biochemical analysis, echocardiography, 6-minute walking test and cardiopulmonary stress testing were performed. Results: Patients in group 1 were significantly older than patients in group 3 (60.4 ± 11.1 years vs. 49.25 ± 11.2 years, respectively, p<0.05). Patients in group 2 had significantly higher BMI in comparison to group 3 (29.8 ± 4.4 vs. 25.1 ± 4.2; p<0.05). Interestingly, patients in group 1 had significantly lower peak oxygen uptake (10.2 ± 3.1 ml/kg/min vs. 16.1 ± 3.5 ml/kg/min, p<0.05) and oxygen uptake at anaerobic treshold (7.9 ± 2.4 ml/kg/min vs. 10.7 ± 1.9 ml/kg/min, p<0.05). Conclusions: Diminished renal function in patients with stable, advanced HFrEF may be associated with significantly worse peak VO2 and VO2 in AT.

show abstract

Section: Discussionmentioning

confidence: 51%

The impact of renal function on clinical and biochemical characteristics in advanced heart failure patients

Bohdan¹,

Frankiewicz²,

Gruchała³

2019

Eur J Trans Clin Med

View full text Add to dashboard Cite

show abstract

“…Previous studies indicated that pressure and volume overload were the major contributors to LVH in CKD. However, LVH still develops even after mitigating these 2 factors [63]. Recent data prefer to pay more attention on the role of Klotho in CKD-induced LVH.…”

Section: The Role Of Klotho In Left Ventricular Hypertrophymentioning

confidence: 99%

The Protective Role of Klotho in CKD-Associated Cardiovascular Disease

Yang

Zhang

et al. 2020

Kidney Dis

View full text Add to dashboard Cite

Background: Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in advanced CKD. The major pathological changes of CKD-associated CVD are severe vascular media calcification, aberrant cardiac remodeling such as hypertrophy and fibrosis, as well as accelerated atherosclerosis. α-Klotho is proposed as an anti-aging gene, which is primarily expressed in the kidney. Recent studies reveal that α-Klotho deficiency is associated with profound cardiovascular dysfunction. Of note, CKD represents extremely declined α-Klotho levels, hinting that α-Klotho deficiency may be implicated in the pathogenesis of CKD-associated CVD. Summary: Based on the pathogenic mechanism of α-Klotho deficiency and decreased Klotho levels in the circulation even early in stage 1 of CKD, α-Klotho serves as a sensitive biomarker for renal insufficiency and also a novel predictor of risk of overall mortality of CVD events in CKD. Meanwhile, loss of Klotho resulted from kidney dysfunction markedly contributes to the progressive development of CKD and CVD. By contrast, prevention of Klotho decline using exogenous supplementation or genetically activated ways by several mechanisms can dramatically mitigate cardiac dysfunction, prevent vascular calcification, and retard the progression of CKD-accelerated atherosclerosis. Key Messages: Klotho deficiency is proposed as a novel predictive biomarker as well as a pathogenic contributor to CVD events in CKD. In the future, Klotho may be a crucial potential therapeutic strategy to decrease the burden of CVD comorbidity with CKD in clinics.

show abstract

“…As terapias atuais recomendadas para ICC demonstraram melhorar a qualidade de vida e a sobrevivência dos pacientes, entretanto podem comprometer a função renal (Grande et al, 2017).…”

Section: Tratamento Da Scr Tipo IIunclassified

Síndrome Cardiorrenal tipo II: bases fisiopatológicas e terapêuticas em cães e gatos

et al. 2020

View full text Add to dashboard Cite

A Síndrome Cardiorrenal (SCR) do tipo II é reconhecida por anormalidades crônicas da função cardíaca que promove lesão e disfunção renal. Nessa revisão de literatura será discutida a compreensão atual, mecanismos fisiopatológicos, aspectos etiológicos e clínicos, bem como a adequação terapêutica de cães e gatos acometidos pela síndrome cardiorrenal do tipo II. Devido à complexidade da síndrome, refletir sobre os diversos mecanismos fisiopatológicos torna-se essencial na continuidade de pesquisas em cães e gatos relacionadas ao diagnóstico precoce e, principalmente, pontos importantes a serem enfatizados no tratamento, com o intuito de obter melhores resultados na terapia de pacientes cardiorrenais.

show abstract

Heart Failure and Kidney Disease

Cited by 25 publications

References 131 publications

The impact of renal function on clinical and biochemical characteristics in advanced heart failure patients

The impact of renal function on clinical and biochemical characteristics in advanced heart failure patients

The Protective Role of Klotho in CKD-Associated Cardiovascular Disease

Síndrome Cardiorrenal tipo II: bases fisiopatológicas e terapêuticas em cães e gatos

Contact Info

Product

Resources

About